ATOS has been granted a new patent
Dec 25, 2024, 11:34 PM
-8.84%
What does ATOS do
Atossa Therapeutics, based in Seattle, focuses on developing oral (Z)-endoxifen for breast cancer treatment and prevention, having completed four Phase I and two Phase II clinical studies. The company went public on November 8, 2012, and employs 10 people.
ATOS filed a patent for "keto acid biopolymers and uses thereof" on Tue, January 3, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.